Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company’s fully-human anti-CD3 monoclonal antibody.
The drug will be provided under the Food & Drug Administration’s individual patient expanded access protocol overseen by researchers at the Brigham and Women’s Hospital (BWH), Harvard.
This is the first time a nasally administered antibody has been given to a patient with SPMS.
Sufferers of multiple sclerosis have limited treatment options with Tysabri, sold by Biogen Inc (NASDAQ:BIIB), one of the few drugs offering relief.
The treatment has been safely administered in a previous trial in people with Covid and was shown to be well-tolerated with no drug-related safety issues.
Nasal Foralumab was developed by Howard Weiner, chairman of Tiziana’s scientific advisory board and a professor at BWH.
He said: “Nasally administered anti-CD3 is an exciting, novel approach that has the ability to provide safe treatment for a form of MS that currently has no effective treatment.
“We are excited to examine this first-in-class approach to treat patients with SPMS for whom no effective treatment option is currently available.”